#begin document (en_1026.txt); part 000
en_1026.txt	0	0	How	WRB	(TOP(SBARQ(WHADVP*)	-	-	-	-	*	-
en_1026.txt	0	1	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	2	Beat	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	3	Childhood	NNP	(NP*	-	-	-	-	*	-
en_1026.txt	0	4	Cancer	NNP	*))))))	-	-	-	-	*	-

en_1026.txt	0	0	PHILADELPHIA	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_1026.txt	0	1	–	SYM	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	2	For	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	a	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	4	parent	NN	*)))))	-	-	-	-	*	-
en_1026.txt	0	5	,	,	*	-	-	-	-	*	-
en_1026.txt	0	6	there	EX	(NP*)	-	-	-	-	*	-
en_1026.txt	0	7	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	perhaps	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	9	no	RB	(NP(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	10	greater	JJR	*)	-	-	-	-	*	-
en_1026.txt	0	11	fear	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	than	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	14	prospect	NN	*)	-	-	-	-	*	-
en_1026.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	losing	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	17	a	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	18	child	NN	*)	-	-	-	-	*	-
en_1026.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_1026.txt	0	20	illness	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	21	or	CC	*	-	-	-	-	*	-
en_1026.txt	0	22	accident	NN	*)))))))))	-	-	-	-	*	-
en_1026.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	And	CC	(TOP(S*	-	-	-	-	*	-
en_1026.txt	0	1	it	PRP	(NP*)	-	-	-	-	*	-
en_1026.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	3	childhood	NN	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	4	cancer	NN	*)	-	-	-	-	*	-
en_1026.txt	0	5	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	6	has	VBZ	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	7	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	8	greatest	JJS	*	-	-	-	-	*	-
en_1026.txt	0	9	potential	NN	*	-	-	-	-	*	-
en_1026.txt	0	10	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	11	catapult	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	12	a	DT	(NP(NP*	-	-	-	-	*	(0
en_1026.txt	0	13	remote	JJ	*	-	-	-	-	*	-
en_1026.txt	0	14	fear	NN	*)	-	-	-	-	*	-
en_1026.txt	0	15	into	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	an	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	17	unimaginable	JJ	*	-	-	-	-	*	-
en_1026.txt	0	18	reality	NN	*))))))))))))	-	-	-	-	*	0)
en_1026.txt	0	19	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	a	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	2	pediatric	JJ	*	-	-	-	-	*	-
en_1026.txt	0	3	oncologist	NN	*))	-	-	-	-	*	-
en_1026.txt	0	4	,	,	*	-	-	-	-	*	-
en_1026.txt	0	5	having	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	6	cared	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	8	children	NNS	(NP(NP*)	-	-	-	-	*	(1
en_1026.txt	0	9	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	10	cancer	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	11	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	12	their	PRP$	(NP*	-	-	-	-	*	(1)
en_1026.txt	0	13	families	NNS	*)))))	-	-	-	-	*	1)
en_1026.txt	0	14	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	more	JJR	(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	16	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	17	25	CD	*)	-	-	-	-	*	-
en_1026.txt	0	18	years	NNS	*)))))	-	-	-	-	*	-
en_1026.txt	0	19	,	,	*	-	-	-	-	*	-
en_1026.txt	0	20	I	PRP	(NP*)	-	-	-	-	*	(2)
en_1026.txt	0	21	know	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	22	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	23	only	RB	(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	24	a	DT	*	-	-	-	-	*	-
en_1026.txt	0	25	parent	NN	*)	-	-	-	-	*	-
en_1026.txt	0	26	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	27	has	VBZ	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	28	confronted	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	29	such	PDT	(NP*	-	-	-	-	*	(3
en_1026.txt	0	30	a	DT	*	-	-	-	-	*	-
en_1026.txt	0	31	diagnosis	NN	*))))))	-	-	-	-	*	3)
en_1026.txt	0	32	truly	RB	(VP(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	33	understands	VBZ	*	-	-	-	-	*	-
en_1026.txt	0	34	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	35	depth	NN	*)	-	-	-	-	*	-
en_1026.txt	0	36	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	37	this	DT	(NP*	-	-	-	-	*	(0
en_1026.txt	0	38	fear	NN	*)))	-	-	-	-	*	0)
en_1026.txt	0	39	,	,	*	-	-	-	-	*	-
en_1026.txt	0	40	as	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	41	it	PRP	(S(NP*)	-	-	-	-	*	(3)
en_1026.txt	0	42	touches	NNS	(VP*	-	-	-	-	*	-
en_1026.txt	0	43	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	44	core	NN	*)	-	-	-	-	*	-
en_1026.txt	0	45	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	46	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	47	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	48	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	49	as	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	50	parents	NNS	(NP*))))))))))))))	-	-	-	-	*	-
en_1026.txt	0	51	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	I	PRP	(TOP(S(NP*)	-	-	-	-	*	(2)
en_1026.txt	0	1	also	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	2	know	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	3	that	IN	(SBAR(SBAR*	-	-	-	-	*	-
en_1026.txt	0	4	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	5	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	6	treating	VBG	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	more	JJR	(NP*	-	-	-	-	*	-
en_1026.txt	0	8	children	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	9	more	RBR	(ADVP(ADVP*	-	-	-	-	*	-
en_1026.txt	0	10	effectively	RB	*)	-	-	-	-	*	-
en_1026.txt	0	11	than	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	12	ever	RB	(ADVP*)))	-	-	-	-	*	-
en_1026.txt	0	13	before	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	–	SYM	(NP*))))))	-	-	-	-	*	-
en_1026.txt	0	15	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	16	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	17	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	18	can	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	19	do	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	20	much	RB	(ADVP*	-	-	-	-	*	-
en_1026.txt	0	21	better	RBR	*	-	-	-	-	*	-
en_1026.txt	0	22	still	RB	(ADVP*))))))))	-	-	-	-	*	-
en_1026.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	2	child	NN	*)	-	-	-	-	*	-
en_1026.txt	0	3	born	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	6	1960	NNS	*	-	-	-	-	*	-
en_1026.txt	0	7	'	POS	*)	-	-	-	-	*	-
en_1026.txt	0	8	s	NN	*)))))	-	-	-	-	*	-
en_1026.txt	0	9	,	,	*	-	-	-	-	*	-
en_1026.txt	0	10	the	DT	(NP(NP*	-	-	-	-	*	(5
en_1026.txt	0	11	diagnosis	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	14	most	RBS	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	15	common	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	16	form	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	18	childhood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	19	cancer	NN	*))))	-	-	-	-	*	-
en_1026.txt	0	20	,	,	*	-	-	-	-	*	-
en_1026.txt	0	21	acute	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	22	lymphoblastic	NN	*	-	-	-	-	*	-
en_1026.txt	0	23	leukemia	NN	*)	-	-	-	-	*	-
en_1026.txt	0	24	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1026.txt	0	25	ALL	NNP	(NP*)	-	-	-	-	*	(6)
en_1026.txt	0	26	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1026.txt	0	27	,	,	*)	-	-	-	-	*	5)
en_1026.txt	0	28	meant	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	29	almost	RB	(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	30	certain	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	31	death	NN	*)	-	-	-	-	*	-
en_1026.txt	0	32	,	,	*	-	-	-	-	*	-
en_1026.txt	0	33	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	34	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	35	survival	NN	*	-	-	-	-	*	-
en_1026.txt	0	36	rate	NN	*)	-	-	-	-	*	-
en_1026.txt	0	37	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	38	less	JJR	(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	39	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	40	10	CD	*)	-	-	-	-	*	-
en_1026.txt	0	41	%	NN	*)))))	-	-	-	-	*	-
en_1026.txt	0	42	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	A	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	1	child	NN	*)	-	-	-	-	*	-
en_1026.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	the	DT	(NP*	-	-	-	-	*	(5
en_1026.txt	0	4	same	JJ	*	-	-	-	-	*	-
en_1026.txt	0	5	diagnosis	NN	*)))	-	-	-	-	*	5)
en_1026.txt	0	6	today	NN	(NP*)	-	-	-	-	*	(7)
en_1026.txt	0	7	has	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	9	better	JJR	(ADJP(QP*	-	-	-	-	*	-
en_1026.txt	0	10	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	11	80	CD	*)	-	-	-	-	*	-
en_1026.txt	0	12	%	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	chance	NN	*)	-	-	-	-	*	-
en_1026.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	being	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	16	cured	VBN	(VP*))))))	-	-	-	-	*	-
en_1026.txt	0	17	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Looking	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_1026.txt	0	1	at	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	2	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	3	five-year	JJ	*	-	-	-	-	*	-
en_1026.txt	0	4	survival	NN	*	-	-	-	-	*	-
en_1026.txt	0	5	rates	NNS	*))	-	-	-	-	*	-
en_1026.txt	0	6	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	7	children	NNS	(NP(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	8	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	9	ALL	NNP	(NP*)))	-	-	-	-	*	(6)
en_1026.txt	0	10	from	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	11	the	DT	(NP(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	12	1970	NNS	*	-	-	-	-	*	-
en_1026.txt	0	13	'	POS	*)	-	-	-	-	*	-
en_1026.txt	0	14	s	NN	*)	-	-	-	-	*	-
en_1026.txt	0	15	through	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	the	DT	(NP(NP*	-	-	-	-	*	(8|(9
en_1026.txt	0	17	1990	CD	*	-	-	-	-	*	-
en_1026.txt	0	18	'	POS	*)	-	-	-	-	*	8)
en_1026.txt	0	19	s	NN	*))))))))	-	-	-	-	*	9)
en_1026.txt	0	20	,	,	*	-	-	-	-	*	-
en_1026.txt	0	21	one	NN	(NP*)	-	-	-	-	*	-
en_1026.txt	0	22	sees	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	23	an	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	24	almost	RB	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	25	linear	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	26	improvement	NN	*)	-	-	-	-	*	-
en_1026.txt	0	27	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	28	cure	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	29	rates	NNS	*))))	-	-	-	-	*	-
en_1026.txt	0	30	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	This	DT	(TOP(S(S(NP*)	-	-	-	-	*	-
en_1026.txt	0	1	makes	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	3	1970s	CD	*)	-	-	-	-	*	-
en_1026.txt	0	4	,	,	*	-	-	-	-	*	-
en_1026.txt	0	5	1980	CD	*	-	-	-	-	*	-
en_1026.txt	0	6	'	:	*	-	-	-	-	*	-
en_1026.txt	0	7	s	PRP	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	8	,	,	*	-	-	-	-	*	-
en_1026.txt	0	9	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	10	1990	CD	*))))	-	-	-	-	*	-
en_1026.txt	0	11	'	:	*	-	-	-	-	*	-
en_1026.txt	0	12	s	PRP	(S(NP*)	-	-	-	-	*	-
en_1026.txt	0	13	look	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	14	like	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	an	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	16	era	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	18	accelerating	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	19	discovery	NN	*)	-	-	-	-	*	-
en_1026.txt	0	20	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	21	therapeutic	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	22	development	NN	*)))))))	-	-	-	-	*	-
en_1026.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	But	CC	(TOP(S*	-	-	-	-	*	-
en_1026.txt	0	1	virtually	RB	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	2	all	DT	*)	-	-	-	-	*	-
en_1026.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	5	drugs	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	6	that	IN	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	7	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	8	use	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	today	NN	(S(NP*)	-	-	-	-	*	(7)
en_1026.txt	0	10	to	TO	(VP*	-	-	-	-	*	-
en_1026.txt	0	11	cure	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	12	children	NNS	(NP*)	-	-	-	-	*	-
en_1026.txt	0	13	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	cancer	NN	(NP*)))))))))))	-	-	-	-	*	-
en_1026.txt	0	15	were	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	16	discovered	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	17	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	18	approved	VBN	*	-	-	-	-	*	-
en_1026.txt	0	19	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	20	the	DT	(NP(NP(NP*	-	-	-	-	*	(10|(9|(11
en_1026.txt	0	21	1950	NNS	*	-	-	-	-	*	-
en_1026.txt	0	22	'	POS	*)	-	-	-	-	*	10)
en_1026.txt	0	23	s	NN	*	-	-	-	-	*	-
en_1026.txt	0	24	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	25	1960	NNS	*	-	-	-	-	*	-
en_1026.txt	0	26	'	POS	*)	-	-	-	-	*	9)
en_1026.txt	0	27	s	NN	*))))	-	-	-	-	*	11)
en_1026.txt	0	28	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	So	RB	(TOP(SBARQ*	-	-	-	-	*	-
en_1026.txt	0	1	,	,	*	-	-	-	-	*	-
en_1026.txt	0	2	if	IN	(SBARQ(SBAR*	-	-	-	-	*	-
en_1026.txt	0	3	new	JJ	(S(NP*	-	-	-	-	*	-
en_1026.txt	0	4	drugs	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	5	did	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	6	not	RB	*	-	-	-	-	*	-
en_1026.txt	0	7	fuel	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	four	CD	(NP*	-	-	-	-	*	-
en_1026.txt	0	9	decades	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	10	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	11	progress	NN	(NP*))))))	-	-	-	-	*	-
en_1026.txt	0	12	,	,	*	-	-	-	-	*	-
en_1026.txt	0	13	what	WP	(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	14	did	VBD	(SQ(VP*))	-	-	-	-	*	-
en_1026.txt	0	15	?	.	*)))	-	-	-	-	*	-

en_1026.txt	0	0	A	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1026.txt	0	1	major	JJ	*	-	-	-	-	*	-
en_1026.txt	0	2	driver	NN	*)	-	-	-	-	*	-
en_1026.txt	0	3	was	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	4	a	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	remarkable	JJ	*	-	-	-	-	*	-
en_1026.txt	0	6	,	,	*	-	-	-	-	*	-
en_1026.txt	0	7	sustained	JJ	*	-	-	-	-	*	-
en_1026.txt	0	8	scientific	JJ	*	-	-	-	-	*	-
en_1026.txt	0	9	collaboration	NN	*))	-	-	-	-	*	-
en_1026.txt	0	10	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	(10|(11
en_1026.txt	0	2	1950	NNS	*	-	-	-	-	*	-
en_1026.txt	0	3	'	POS	*)	-	-	-	-	*	10)
en_1026.txt	0	4	s	NN	*))	-	-	-	-	*	11)
en_1026.txt	0	5	,	,	*	-	-	-	-	*	-
en_1026.txt	0	6	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	7	group	NN	*)	-	-	-	-	*	-
en_1026.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	9	clinical	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	10	scientists	NNS	*)))	-	-	-	-	*	-
en_1026.txt	0	11	recognized	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	12	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	13	,	,	*	-	-	-	-	*	-
en_1026.txt	0	14	because	IN	(S(SBAR*	-	-	-	-	*	-
en_1026.txt	0	15	childhood	NN	(S(NP*	-	-	-	-	*	-
en_1026.txt	0	16	cancer	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	was	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	18	a	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	19	rare	JJ	*	-	-	-	-	*	-
en_1026.txt	0	20	disease	NN	*))))	-	-	-	-	*	-
en_1026.txt	0	21	,	,	*	-	-	-	-	*	-
en_1026.txt	0	22	no	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	23	single	JJ	*	-	-	-	-	*	-
en_1026.txt	0	24	medical	JJ	*	-	-	-	-	*	-
en_1026.txt	0	25	center	NN	*)	-	-	-	-	*	-
en_1026.txt	0	26	could	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	27	study	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	28	enough	RB	(NP*	-	-	-	-	*	-
en_1026.txt	0	29	patients	NNS	*	-	-	-	-	*	-
en_1026.txt	0	30	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	31	make	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	32	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	33	necessary	JJ	*	-	-	-	-	*	-
en_1026.txt	0	34	advances	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	35	across	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	36	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	37	spectrum	NN	*)	-	-	-	-	*	-
en_1026.txt	0	38	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	39	pediatric	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	40	oncologic	NN	*	-	-	-	-	*	-
en_1026.txt	0	41	diseases	NNS	*)))))))))))))	-	-	-	-	*	-
en_1026.txt	0	42	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1026.txt	0	1	decision	NN	*	-	-	-	-	*	-
en_1026.txt	0	2	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	3	conduct	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	4	collaborative	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	research	NN	*)	-	-	-	-	*	-
en_1026.txt	0	6	across	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	7	multiple	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	8	institutions	NNS	*))))))	-	-	-	-	*	-
en_1026.txt	0	9	resulted	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	10	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	12	development	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	cooperative	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	15	group	NN	*	-	-	-	-	*	-
en_1026.txt	0	16	research	NN	*)))))	-	-	-	-	*	-
en_1026.txt	0	17	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	In	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	2	fight	NN	*)	-	-	-	-	*	-
en_1026.txt	0	3	against	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	4	childhood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	cancer	NN	*))))	-	-	-	-	*	-
en_1026.txt	0	6	,	,	*	-	-	-	-	*	-
en_1026.txt	0	7	this	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	8	concept	NN	*)	-	-	-	-	*	-
en_1026.txt	0	9	evolved	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	10	into	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	11	what	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	12	is	VBZ	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	13	now	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	14	the	DT	(NP(NP(NP(NP*	-	-	-	-	*	(12
en_1026.txt	0	15	Children	NNS	*	-	-	-	-	*	-
en_1026.txt	0	16	'	POS	*)	-	-	-	-	*	-
en_1026.txt	0	17	s	NNP	*	-	-	-	-	*	-
en_1026.txt	0	18	Oncology	NNP	*	-	-	-	-	*	-
en_1026.txt	0	19	Group	NNP	*)	-	-	-	-	*	-
en_1026.txt	0	20	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1026.txt	0	21	COG	NNP	(NP*)	-	-	-	-	*	-
en_1026.txt	0	22	-RRB-	-RRB-	*))	-	-	-	-	*	12)
en_1026.txt	0	23	,	,	*	-	-	-	-	*	-
en_1026.txt	0	24	which	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	25	unites	VBZ	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	26	more	JJR	(NP(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	27	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	28	8,000	CD	*)	-	-	-	-	*	-
en_1026.txt	0	29	experts	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	30	at	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	31	more	JJR	(NP(NP(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	32	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	33	200	CD	*)	-	-	-	-	*	-
en_1026.txt	0	34	leading	JJ	*	-	-	-	-	*	-
en_1026.txt	0	35	children	NNS	*	-	-	-	-	*	-
en_1026.txt	0	36	'	POS	*)	-	-	-	-	*	-
en_1026.txt	0	37	s	JJ	*	-	-	-	-	*	-
en_1026.txt	0	38	hospitals	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	39	,	,	*	-	-	-	-	*	-
en_1026.txt	0	40	universities	NNS	(NP*)	-	-	-	-	*	-
en_1026.txt	0	41	,	,	*	-	-	-	-	*	-
en_1026.txt	0	42	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	43	cancer	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	44	centers	NNS	*))))	-	-	-	-	*	-
en_1026.txt	0	45	across	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	46	North	NNP	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	47	America	NNP	*)	-	-	-	-	*	-
en_1026.txt	0	48	,	,	*	-	-	-	-	*	-
en_1026.txt	0	49	Australia	NNP	(NP*)	-	-	-	-	*	-
en_1026.txt	0	50	,	,	*	-	-	-	-	*	-
en_1026.txt	0	51	New	NNP	(NP*	-	-	-	-	*	-
en_1026.txt	0	52	Zealand	NNP	*)	-	-	-	-	*	-
en_1026.txt	0	53	,	,	*	-	-	-	-	*	-
en_1026.txt	0	54	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	55	parts	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	56	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	57	Europe	NNP	(NP*))))))))))))))	-	-	-	-	*	-
en_1026.txt	0	58	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	(12
en_1026.txt	0	1	COG	NNP	*)	-	-	-	-	*	12)
en_1026.txt	0	2	conducts	VBZ	(VP(VP*	-	-	-	-	*	-
en_1026.txt	0	3	research	NN	(NP*)	-	-	-	-	*	-
en_1026.txt	0	4	across	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	6	spectrum	NN	*)	-	-	-	-	*	-
en_1026.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	8	cancers	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	9	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	10	afflict	VBP	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	11	children	NNS	(NP*)))))))))	-	-	-	-	*	-
en_1026.txt	0	12	,	,	*	-	-	-	-	*	-
en_1026.txt	0	13	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	14	has	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	15	approximately	RB	(NP(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	16	100	CD	*)	-	-	-	-	*	-
en_1026.txt	0	17	clinical	JJ	*	-	-	-	-	*	-
en_1026.txt	0	18	trials	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	19	underway	JJ	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	20	around	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	21	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	22	world	NN	*))))))	-	-	-	-	*	-
en_1026.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	With	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	an	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	2	emerging	VBG	*	-	-	-	-	*	-
en_1026.txt	0	3	infrastructure	NN	*)	-	-	-	-	*	-
en_1026.txt	0	4	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	5	place	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	6	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	7	cooperative	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	8	research	NN	*))))))	-	-	-	-	*	-
en_1026.txt	0	9	,	,	*	-	-	-	-	*	-
en_1026.txt	0	10	sustained	VBN	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	11	improvement	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	outcomes	NNS	(NP*)))	-	-	-	-	*	-
en_1026.txt	0	14	partly	RB	(VP(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	15	reflected	VBD	*	-	-	-	-	*	-
en_1026.txt	0	16	an	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	17	ever-increasing	JJ	*	-	-	-	-	*	-
en_1026.txt	0	18	understanding	NN	*	-	-	-	-	*	-
en_1026.txt	0	19	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	20	childhood	NN	(S(NP*	-	-	-	-	*	-
en_1026.txt	0	21	cancers	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	22	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	23	diverse	JJ	(ADJP*))))))	-	-	-	-	*	-
en_1026.txt	0	24	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Childhood	NNP	(TOP(S(NP*	-	-	-	-	*	-
en_1026.txt	0	1	ALL	NNP	*)	-	-	-	-	*	-
en_1026.txt	0	2	,	,	*	-	-	-	-	*	-
en_1026.txt	0	3	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	4	example	NN	(NP*))	-	-	-	-	*	-
en_1026.txt	0	5	,	,	*	-	-	-	-	*	-
en_1026.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	not	RB	*	-	-	-	-	*	-
en_1026.txt	0	8	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	9	single	JJ	*	-	-	-	-	*	-
en_1026.txt	0	10	disease	NN	*)	-	-	-	-	*	-
en_1026.txt	0	11	,	,	*	-	-	-	-	*	-
en_1026.txt	0	12	but	CC	(CONJP*	-	-	-	-	*	-
en_1026.txt	0	13	rather	RB	*)	-	-	-	-	*	-
en_1026.txt	0	14	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	15	spectrum	NN	*)	-	-	-	-	*	-
en_1026.txt	0	16	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	17	diseases	NNS	(NP*)))))	-	-	-	-	*	-
en_1026.txt	0	18	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Recognition	NNP	(TOP(S(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	1	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	2	this	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	3	diversity	NN	*)))	-	-	-	-	*	-
en_1026.txt	0	4	led	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_1026.txt	0	6	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	7	study	NN	*)	-	-	-	-	*	-
en_1026.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	9	different	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	10	treatment	NN	*	-	-	-	-	*	-
en_1026.txt	0	11	regimens	NNS	*))))	-	-	-	-	*	-
en_1026.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	different	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	14	sub-populations	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	17	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	18	pathologically	RB	(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	19	similar	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	20	cancers	NNS	*)))))))	-	-	-	-	*	-
en_1026.txt	0	21	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Throughout	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	this	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	2	period	NN	*))	-	-	-	-	*	-
en_1026.txt	0	3	,	,	*	-	-	-	-	*	-
en_1026.txt	0	4	the	DT	(NP(NP*	-	-	-	-	*	(13
en_1026.txt	0	5	ability	NN	*	-	-	-	-	*	-
en_1026.txt	0	6	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	7	overcome	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	9	most	RBS	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	10	common	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	11	side	JJ	*	-	-	-	-	*	-
en_1026.txt	0	12	effect	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	cancer	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	15	drugs	NNS	*)))))))	-	-	-	-	*	-
en_1026.txt	0	16	,	,	*	-	-	-	-	*	-
en_1026.txt	0	17	myelosuppression	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	18	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1026.txt	0	19	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	20	decrease	NN	*)	-	-	-	-	*	-
en_1026.txt	0	21	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	22	blood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	23	counts	NNS	*)))	-	-	-	-	*	-
en_1026.txt	0	24	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1026.txt	0	25	,	,	*)	-	-	-	-	*	13)
en_1026.txt	0	26	improved	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	27	dramatically	RB	(ADVP*))	-	-	-	-	*	-
en_1026.txt	0	28	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	It	PRP	(TOP(S(NP*)	-	-	-	-	*	(13)
en_1026.txt	0	1	began	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	2	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	4	ability	NN	*	-	-	-	-	*	-
en_1026.txt	0	5	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	6	transfuse	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	not	RB	(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	8	only	RB	*	-	-	-	-	*	-
en_1026.txt	0	9	red	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	10	blood	NN	*	-	-	-	-	*	-
en_1026.txt	0	11	cells	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	12	into	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	anemic	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	14	patients	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	15	,	,	*	-	-	-	-	*	-
en_1026.txt	0	16	but	CC	(CONJP*	-	-	-	-	*	-
en_1026.txt	0	17	also	RB	*)	-	-	-	-	*	-
en_1026.txt	0	18	platelets	NNS	(NP*))))))))	-	-	-	-	*	-
en_1026.txt	0	19	,	,	*	-	-	-	-	*	-
en_1026.txt	0	20	reducing	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	21	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	22	threat	NN	*)	-	-	-	-	*	-
en_1026.txt	0	23	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	24	life-threatening	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	25	bleeding	NN	*))	-	-	-	-	*	-
en_1026.txt	0	26	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	27	can	MD	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	28	accompany	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	29	cancer	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	30	therapy	NN	*)))))))))	-	-	-	-	*	-
en_1026.txt	0	31	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Equally	RB	(TOP(S(ADVP*	-	-	-	-	*	-
en_1026.txt	0	1	important	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	2	,	,	*	-	-	-	-	*	-
en_1026.txt	0	3	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	4	risks	NNS	*	-	-	-	-	*	-
en_1026.txt	0	5	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	6	types	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	8	life-threatening	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	9	infections	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	10	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	11	come	VBP	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	12	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	myelosuppression	NN	(NP*))))))))	-	-	-	-	*	-
en_1026.txt	0	14	were	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	15	increasingly	RB	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	16	recognized	VBN	*)	-	-	-	-	*	-
en_1026.txt	0	17	,	,	*	-	-	-	-	*	-
en_1026.txt	0	18	leading	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	19	to	TO	(PP*	-	-	-	-	*	-
en_1026.txt	0	20	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	21	development	NN	*)	-	-	-	-	*	-
en_1026.txt	0	22	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	23	better	JJR	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	24	use	NN	*)	-	-	-	-	*	-
en_1026.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	26	more	RBR	(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	27	effective	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	28	antibiotics	NNS	*))))))))	-	-	-	-	*	-
en_1026.txt	0	29	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Starting	VBG	(TOP(S(S(VP*	-	-	-	-	*	-
en_1026.txt	0	1	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	2	the	DT	(NP(NP*	-	-	-	-	*	(8|(9
en_1026.txt	0	3	1990	CD	*	-	-	-	-	*	-
en_1026.txt	0	4	'	POS	*)	-	-	-	-	*	8)
en_1026.txt	0	5	s	NN	*))))	-	-	-	-	*	9)
en_1026.txt	0	6	,	,	*	-	-	-	-	*	-
en_1026.txt	0	7	cytokines	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	8	,	,	*	-	-	-	-	*	-
en_1026.txt	0	9	drugs	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	10	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	11	stimulate	VB	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	12	bone	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	13	marrow	NN	*)	-	-	-	-	*	-
en_1026.txt	0	14	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	15	produce	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	16	infection-fighting	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	17	white	JJ	*	-	-	-	-	*	-
en_1026.txt	0	18	blood	NN	*	-	-	-	-	*	-
en_1026.txt	0	19	cells	NNS	*))))))))	-	-	-	-	*	-
en_1026.txt	0	20	,	,	*)	-	-	-	-	*	-
en_1026.txt	0	21	began	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	22	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	23	be	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	24	integrated	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	25	into	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	26	cancer	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	27	treatments	NNS	*))))))	-	-	-	-	*	-
en_1026.txt	0	28	,	,	*	-	-	-	-	*	-
en_1026.txt	0	29	further	RB	(S(VP(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	30	mitigating	VBG	*	-	-	-	-	*	-
en_1026.txt	0	31	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	32	risk	NN	*)	-	-	-	-	*	-
en_1026.txt	0	33	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	34	life-threatening	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	35	infectious	JJ	*	-	-	-	-	*	-
en_1026.txt	0	36	complications	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	37	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	38	care	NN	(NP*))))))))	-	-	-	-	*	-
en_1026.txt	0	39	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	As	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	2	result	NN	*)	-	-	-	-	*	-
en_1026.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	4	these	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	5	advances	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	6	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	7	science	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	8	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	9	supportive	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	10	care	NN	*)))))))	-	-	-	-	*	-
en_1026.txt	0	11	,	,	*	-	-	-	-	*	-
en_1026.txt	0	12	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	13	same	JJ	*	-	-	-	-	*	-
en_1026.txt	0	14	chemotherapeutic	JJ	*	-	-	-	-	*	-
en_1026.txt	0	15	drugs	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	16	could	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	17	be	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	18	delivered	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	19	much	RB	(ADVP(ADVP*	-	-	-	-	*	-
en_1026.txt	0	20	more	RBR	*	-	-	-	-	*	-
en_1026.txt	0	21	intensively	RB	*)	-	-	-	-	*	-
en_1026.txt	0	22	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	23	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	24	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	25	select	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	26	types	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	27	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	28	sub-types	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	29	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	30	cancer	NN	(NP*)))))))))))	-	-	-	-	*	-
en_1026.txt	0	31	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	With	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	selective	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	2	intensification	NN	*))	-	-	-	-	*	-
en_1026.txt	0	3	,	,	*	-	-	-	-	*	-
en_1026.txt	0	4	cure	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	rates	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	6	began	VBD	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	8	increase	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	steadily	RB	(ADVP*)))))	-	-	-	-	*	-
en_1026.txt	0	10	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	And	CC	(TOP(S*	-	-	-	-	*	-
en_1026.txt	0	1	yet	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	2	,	,	*	-	-	-	-	*	-
en_1026.txt	0	3	while	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	4	this	DT	(S(NP*	-	-	-	-	*	-
en_1026.txt	0	5	strategy	NN	*)	-	-	-	-	*	-
en_1026.txt	0	6	has	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	indeed	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	8	resulted	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	10	better	JJR	(NP*	-	-	-	-	*	-
en_1026.txt	0	11	outcomes	NNS	*))))))	-	-	-	-	*	-
en_1026.txt	0	12	,	,	*	-	-	-	-	*	-
en_1026.txt	0	13	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	14	acute	JJ	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	15	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	16	long-term	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	17	morbidity	NN	*)	-	-	-	-	*	-
en_1026.txt	0	18	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	19	therapy	NN	(NP*)))	-	-	-	-	*	-
en_1026.txt	0	20	has	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	21	been	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	22	substantial	JJ	(ADJP*)))	-	-	-	-	*	-
en_1026.txt	0	23	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Children	NNS	(TOP(S(NP(NP*)	-	-	-	-	*	(14
en_1026.txt	0	1	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	2	high-risk	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	3	cancers	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	4	who	WP	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	5	receive	VBP	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	6	dose-intensive	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	7	chemotherapy	NN	*)))))))	-	-	-	-	*	14)
en_1026.txt	0	8	have	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	10	greater	JJR	(ADJP(QP*	-	-	-	-	*	-
en_1026.txt	0	11	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	12	80	CD	*)	-	-	-	-	*	-
en_1026.txt	0	13	%	NN	*)	-	-	-	-	*	-
en_1026.txt	0	14	chance	NN	*)	-	-	-	-	*	-
en_1026.txt	0	15	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	experiencing	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	17	at	IN	(NP(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	18	least	JJS	*	-	-	-	-	*	-
en_1026.txt	0	19	one	CD	*)	-	-	-	-	*	-
en_1026.txt	0	20	severe	JJ	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	21	,	,	*	-	-	-	-	*	-
en_1026.txt	0	22	life-threatening	JJ	*	-	-	-	-	*	-
en_1026.txt	0	23	,	,	*	-	-	-	-	*	-
en_1026.txt	0	24	or	CC	*	-	-	-	-	*	-
en_1026.txt	0	25	fatal	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	26	drug-related	JJ	*	-	-	-	-	*	-
en_1026.txt	0	27	toxic	JJ	*	-	-	-	-	*	-
en_1026.txt	0	28	event	NN	*)	-	-	-	-	*	-
en_1026.txt	0	29	over	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	30	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	31	course	NN	*)	-	-	-	-	*	-
en_1026.txt	0	32	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	33	their	PRP$	(NP*	-	-	-	-	*	(14)
en_1026.txt	0	34	treatment	NN	*))))))))))	-	-	-	-	*	-
en_1026.txt	0	35	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	1	late	JJ	*	-	-	-	-	*	-
en_1026.txt	0	2	effects	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	3	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	4	cancer	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	treatment	NN	*)))	-	-	-	-	*	-
en_1026.txt	0	6	include	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	permanent	JJ	(NP(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	8	organ	NN	*)	-	-	-	-	*	-
en_1026.txt	0	9	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	10	tissue	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	11	damage	NN	*))	-	-	-	-	*	-
en_1026.txt	0	12	,	,	*	-	-	-	-	*	-
en_1026.txt	0	13	hormonal	JJ	(NP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	14	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	15	reproductive	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	16	dysfunction	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	,	,	*	-	-	-	-	*	-
en_1026.txt	0	18	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	19	second	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	20	cancers	NNS	*)))	-	-	-	-	*	-
en_1026.txt	0	21	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	More	JJR	(TOP(S(NP(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	1	than	IN	*	-	-	-	-	*	-
en_1026.txt	0	2	40	CD	*)	-	-	-	-	*	-
en_1026.txt	0	3	%	NN	*)	-	-	-	-	*	-
en_1026.txt	0	4	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	6	estimated	JJ	*	-	-	-	-	*	-
en_1026.txt	0	7	330,000	CD	*	-	-	-	-	*	-
en_1026.txt	0	8	survivors	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	9	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	10	childhood	NN	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	11	cancer	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	the	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	14	United	NNP	*	-	-	-	-	*	-
en_1026.txt	0	15	States	NNPS	*)))))))	-	-	-	-	*	-
en_1026.txt	0	16	experience	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	17	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	18	significant	JJ	*	-	-	-	-	*	-
en_1026.txt	0	19	health-related	JJ	*	-	-	-	-	*	-
en_1026.txt	0	20	complication	NN	*)	-	-	-	-	*	-
en_1026.txt	0	21	from	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	22	childhood	NN	(NP(NP*	-	-	-	-	*	(15
en_1026.txt	0	23	cancer	NN	*)	-	-	-	-	*	15)
en_1026.txt	0	24	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	25	its	PRP$	(NP*	-	-	-	-	*	(15)
en_1026.txt	0	26	treatment	NN	*)))))	-	-	-	-	*	-
en_1026.txt	0	27	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	And	CC	(TOP(S*	-	-	-	-	*	-
en_1026.txt	0	1	,	,	(PRN*	-	-	-	-	*	-
en_1026.txt	0	2	despite	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	our	PRP$	(NP*	-	-	-	-	*	(4)
en_1026.txt	0	4	advances	NNS	*))	-	-	-	-	*	-
en_1026.txt	0	5	,	,	*)	-	-	-	-	*	-
en_1026.txt	0	6	cancer	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	7	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	8	developed	VBN	(NP*	-	-	-	-	*	-
en_1026.txt	0	9	countries	NNS	*)))	-	-	-	-	*	-
en_1026.txt	0	10	remains	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	12	leading	VBG	*	-	-	-	-	*	-
en_1026.txt	0	13	cause	NN	*)	-	-	-	-	*	-
en_1026.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	death	NN	(NP*))	-	-	-	-	*	-
en_1026.txt	0	16	from	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	17	disease	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	18	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	19	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	20	older	JJR	(ADJP(ADJP*)	-	-	-	-	*	-
en_1026.txt	0	21	than	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	22	one	CD	(NP*	-	-	-	-	*	-
en_1026.txt	0	23	year	NN	*)))))))))	-	-	-	-	*	-
en_1026.txt	0	24	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	We	PRP	(TOP(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	1	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	2	,	,	*	-	-	-	-	*	-
en_1026.txt	0	3	however	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	4	,	,	*	-	-	-	-	*	-
en_1026.txt	0	5	entering	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	6	an	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	7	era	NN	*)	-	-	-	-	*	-
en_1026.txt	0	8	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	9	unprecedented	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	10	discovery	NN	*))))))	-	-	-	-	*	-
en_1026.txt	0	11	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	1	powerful	JJ	*	-	-	-	-	*	-
en_1026.txt	0	2	research	NN	*	-	-	-	-	*	-
en_1026.txt	0	3	tools	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	4	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	5	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	6	now	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	7	have	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	9	uncover	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	10	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	11	underlying	VBG	*	-	-	-	-	*	-
en_1026.txt	0	12	basis	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	childhood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	15	cancers	NNS	*))))))))))	-	-	-	-	*	-
en_1026.txt	0	16	could	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	17	fundamentally	RB	(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	18	change	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	19	how	WRB	(SBAR(WHADVP*)	-	-	-	-	*	-
en_1026.txt	0	20	we	PRP	(S(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	21	treat	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	22	children	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	23	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	24	these	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	25	dreaded	JJ	*	-	-	-	-	*	-
en_1026.txt	0	26	diseases	NNS	*))))))))	-	-	-	-	*	-
en_1026.txt	0	27	.	.	*	-	-	-	-	*	-
en_1026.txt	0	28	For	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	29	a	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	30	limited	VBN	*	-	-	-	-	*	-
en_1026.txt	0	31	number	NN	*)	-	-	-	-	*	-
en_1026.txt	0	32	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	33	childhood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	34	cancers	NNS	*))))	-	-	-	-	*	-
en_1026.txt	0	35	,	,	*	-	-	-	-	*	-
en_1026.txt	0	36	there	EX	(NP*)	-	-	-	-	*	-
en_1026.txt	0	37	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	38	new	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	39	drugs	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	40	that	WDT	(SBAR(WHNP*)	-	-	-	-	*	-
en_1026.txt	0	41	can	MD	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	42	target	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	43	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	44	fundamental	JJ	*	-	-	-	-	*	-
en_1026.txt	0	45	drivers	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	46	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	47	malignancy	NN	(NP*)))))))))	-	-	-	-	*	-
en_1026.txt	0	48	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1026.txt	0	1	most	RBS	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	2	notable	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	3	example	NN	*)	-	-	-	-	*	-
en_1026.txt	0	4	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	5	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	6	impact	NN	*)	-	-	-	-	*	-
en_1026.txt	0	7	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	8	Gleevec	NNP	(NP(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	9	-LRB-	-LRB-	(PRN*	-	-	-	-	*	-
en_1026.txt	0	10	imatinib	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	11	mesylate	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	-RRB-	-RRB-	*))	-	-	-	-	*	-
en_1026.txt	0	13	on	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	outcomes	NNS	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	15	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	16	children	NNS	(NP(NP*)	-	-	-	-	*	(16
en_1026.txt	0	17	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	18	an	DT	(NP(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	19	uncommon	JJ	*	-	-	-	-	*	-
en_1026.txt	0	20	subtype	NN	*)	-	-	-	-	*	-
en_1026.txt	0	21	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	22	leukemia	NN	(NP*))	-	-	-	-	*	-
en_1026.txt	0	23	–	SYM	(X*))	-	-	-	-	*	-
en_1026.txt	0	24	Philadelphia	NNP	(NP*	-	-	-	-	*	-
en_1026.txt	0	25	chromosome-positive	NN	*	-	-	-	-	*	-
en_1026.txt	0	26	ALL	NNP	*)))))))))))	-	-	-	-	*	16)
en_1026.txt	0	27	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	1	addition	NN	*)	-	-	-	-	*	-
en_1026.txt	0	2	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	this	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	4	inhibitor	NN	*))	-	-	-	-	*	-
en_1026.txt	0	5	to	TO	(PP*	-	-	-	-	*	-
en_1026.txt	0	6	intensive	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	7	chemotherapy	NN	*)))	-	-	-	-	*	-
en_1026.txt	0	8	has	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	dramatically	RB	(VP(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	10	improved	VBN	*	-	-	-	-	*	-
en_1026.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	12	outlook	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	these	DT	(NP*	-	-	-	-	*	(16
en_1026.txt	0	15	children	NNS	*)))	-	-	-	-	*	16)
en_1026.txt	0	16	,	,	*	-	-	-	-	*	-
en_1026.txt	0	17	increasing	VBG	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	18	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	19	rate	NN	*)	-	-	-	-	*	-
en_1026.txt	0	20	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	21	three-year	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	22	event-free	JJ	*	-	-	-	-	*	-
en_1026.txt	0	23	survival	NN	*)))	-	-	-	-	*	-
en_1026.txt	0	24	from	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	25	35	CD	(NP(QP*	-	-	-	-	*	-
en_1026.txt	0	26	%	NN	*	-	-	-	-	*	-
en_1026.txt	0	27	to	TO	*	-	-	-	-	*	-
en_1026.txt	0	28	80	CD	*	-	-	-	-	*	-
en_1026.txt	0	29	%	NN	*)))))))	-	-	-	-	*	-
en_1026.txt	0	30	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	1	development	NN	*)	-	-	-	-	*	-
en_1026.txt	0	2	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	3	targeted	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	4	new	JJ	*	-	-	-	-	*	-
en_1026.txt	0	5	agents	NNS	*)))	-	-	-	-	*	-
en_1026.txt	0	6	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	7	likely	JJ	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	8	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	9	affect	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	10	outcomes	NNS	(NP*)	-	-	-	-	*	-
en_1026.txt	0	11	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	12	other	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	13	subtypes	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	14	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	childhood	NN	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	16	cancer	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	,	,	*	-	-	-	-	*	-
en_1026.txt	0	18	including	VBG	(PP*	-	-	-	-	*	-
en_1026.txt	0	19	anaplastic	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	20	large-cell	JJ	*	-	-	-	-	*	-
en_1026.txt	0	21	lymphoma	NN	*)	-	-	-	-	*	-
en_1026.txt	0	22	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	23	other	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	24	types	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	25	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	26	leukemias	NNS	(NP*))))))))))))))	-	-	-	-	*	-
en_1026.txt	0	27	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Given	VBN	(TOP(S(S(VP*	-	-	-	-	*	-
en_1026.txt	0	1	that	IN	(SBAR*	-	-	-	-	*	-
en_1026.txt	0	2	childhood	NN	(S(NP*	-	-	-	-	*	-
en_1026.txt	0	3	cancers	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	4	are	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	5	all	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	6	rare	JJ	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	7	or	CC	*	-	-	-	-	*	-
en_1026.txt	0	8	ultra-rare	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	9	diseases	NNS	*))))))	-	-	-	-	*	-
en_1026.txt	0	10	,	,	*	-	-	-	-	*	-
en_1026.txt	0	11	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	12	ability	NN	*)	-	-	-	-	*	-
en_1026.txt	0	13	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	14	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	15	biopharmaceutical	JJ	*	-	-	-	-	*	-
en_1026.txt	0	16	industry	NN	*)	-	-	-	-	*	-
en_1026.txt	0	17	to	TO	(SBAR(S(VP*	-	-	-	-	*	-
en_1026.txt	0	18	invest	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	19	resources	NNS	(NP*)	-	-	-	-	*	-
en_1026.txt	0	20	into	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	21	development	NN	(NP(NP*)	-	-	-	-	*	-
en_1026.txt	0	22	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	23	new	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	24	treatments	NNS	*)))))))))))	-	-	-	-	*	-
en_1026.txt	0	25	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	26	limited	JJ	(ADJP*)	-	-	-	-	*	-
en_1026.txt	0	27	at	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	28	best	RBS	*))	-	-	-	-	*	-
en_1026.txt	0	29	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Yet	CC	(TOP(S*	-	-	-	-	*	-
en_1026.txt	0	1	research	NN	(NP*)	-	-	-	-	*	-
en_1026.txt	0	2	is	VBZ	(VP*	-	-	-	-	*	-
en_1026.txt	0	3	needed	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	4	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	5	identify	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	6	potential	JJ	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	7	targets	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	8	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	10	entire	JJ	*	-	-	-	-	*	-
en_1026.txt	0	11	spectrum	NN	*)	-	-	-	-	*	-
en_1026.txt	0	12	of	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	13	childhood	NN	(NP*	-	-	-	-	*	-
en_1026.txt	0	14	cancers	NNS	*))))))))))	-	-	-	-	*	-
en_1026.txt	0	15	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	For	IN	(TOP(S(PP*	-	-	-	-	*	-
en_1026.txt	0	1	some	DT	(NP*	-	-	-	-	*	-
en_1026.txt	0	2	potential	JJ	*	-	-	-	-	*	-
en_1026.txt	0	3	targets	NNS	*))	-	-	-	-	*	-
en_1026.txt	0	4	,	,	*	-	-	-	-	*	-
en_1026.txt	0	5	public-private	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	6	partnerships	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	7	will	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	8	be	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	needed	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	10	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	11	develop	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	12	new	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	13	therapeutic	JJ	*	-	-	-	-	*	-
en_1026.txt	0	14	approaches	NNS	*)))))))	-	-	-	-	*	-
en_1026.txt	0	15	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	The	DT	(TOP(S(NP*	-	-	-	-	*	-
en_1026.txt	0	1	past	JJ	*	-	-	-	-	*	-
en_1026.txt	0	2	40	CD	*	-	-	-	-	*	-
en_1026.txt	0	3	years	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	4	have	VBP	(VP*	-	-	-	-	*	-
en_1026.txt	0	5	demonstrated	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	6	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	7	remarkable	JJ	*	-	-	-	-	*	-
en_1026.txt	0	8	return	NN	*)	-	-	-	-	*	-
en_1026.txt	0	9	on	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	10	investment	NN	(NP*)))	-	-	-	-	*	-
en_1026.txt	0	11	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	12	be	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	13	gained	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	14	in	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	15	collaborative	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	16	scientific	JJ	*	-	-	-	-	*	-
en_1026.txt	0	17	research	NN	*))))))))	-	-	-	-	*	-
en_1026.txt	0	18	.	.	*))	-	-	-	-	*	-

en_1026.txt	0	0	Now	RB	(TOP(S(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	1	we	PRP	(NP*)	-	-	-	-	*	(4)
en_1026.txt	0	2	must	MD	(VP*	-	-	-	-	*	-
en_1026.txt	0	3	leverage	VB	(VP(VP*	-	-	-	-	*	-
en_1026.txt	0	4	current	JJ	(NP*	-	-	-	-	*	-
en_1026.txt	0	5	scientific	JJ	*	-	-	-	-	*	-
en_1026.txt	0	6	opportunities	NNS	*))	-	-	-	-	*	-
en_1026.txt	0	7	and	CC	*	-	-	-	-	*	-
en_1026.txt	0	8	invest	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	9	the	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	10	resources	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	11	needed	VBN	(VP*	-	-	-	-	*	-
en_1026.txt	0	12	to	TO	(S(VP*	-	-	-	-	*	-
en_1026.txt	0	13	develop	VB	(VP*	-	-	-	-	*	-
en_1026.txt	0	14	more	RBR	(NP(ADJP(ADJP*	-	-	-	-	*	-
en_1026.txt	0	15	effective	JJ	*)	-	-	-	-	*	-
en_1026.txt	0	16	,	,	*	-	-	-	-	*	-
en_1026.txt	0	17	less	RBR	(ADJP*	-	-	-	-	*	-
en_1026.txt	0	18	toxic	JJ	*))	-	-	-	-	*	-
en_1026.txt	0	19	therapies	NNS	*))))))	-	-	-	-	*	-
en_1026.txt	0	20	,	,	*	-	-	-	-	*	-
en_1026.txt	0	21	thereby	RB	(S(VP(ADVP*)	-	-	-	-	*	-
en_1026.txt	0	22	improving	VBG	*	-	-	-	-	*	-
en_1026.txt	0	23	outcomes	NNS	(NP*)	-	-	-	-	*	-
en_1026.txt	0	24	for	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	25	all	DT	(NP(NP*	-	-	-	-	*	-
en_1026.txt	0	26	children	NNS	*)	-	-	-	-	*	-
en_1026.txt	0	27	with	IN	(PP*	-	-	-	-	*	-
en_1026.txt	0	28	cancer	NN	(NP*)))))))))	-	-	-	-	*	-
en_1026.txt	0	29	.	.	*))	-	-	-	-	*	-

#end document
